AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts

AbbVie (NYSE:ABBV) reported new Phase 2a data for ABBV-466 in Crohn's disease at recent major medical meetings. The dual-targeting ABBV-466 therapy produced higher endoscopic remission rates than single-pathway treatments in the Phase 2a study. Management flagged multiple new and updated presentations on its solid tumor pipeline for the 2026 ESMO Congress. The ABBV-466 Crohn's data and upcoming oncology results only capture part of what investors may want to assess on AbbVie today. Take a...